SPNGNX_logo_hrz.jpg
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis
07 juin 2021 07h00 HE | Spinogenix, Inc.
SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) -- Spinogenix, Inc. a pharmaceutical company focused on the development of novel synaptogenic small molecule therapies for central nervous system disorders...
SPNGNX_logo_hrz.jpg
Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)
05 janv. 2021 05h00 HE | Spinogenix, Inc.
SAN DIEGO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Spinogenix, Inc. a preclinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced...
Spinogenix Awarded NIH Grant to Develop Novel Neurorestorative Therapeutics for Alzheimer’s Disease
01 mai 2018 14h23 HE | Spinogenix, Inc.
SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a preclinical stage, privately-held pharmaceutical company developing first-in-class drugs to reverse synapse loss and restore...
Medable_BoltLogo_FinalBlue-01 (1).jpg
Medable Launches Synapse, a Fully Integrated Clinical Care App Platform Using CareKit
09 juin 2017 13h10 HE | Medable
PALO ALTO, Calif., June 09, 2017 (GLOBE NEWSWIRE) -- Medable Inc.--the leading app and analytics platform for healthcare--today announced the release of Synapse, the first cloud solution to enable...
Synapse Marketing Solutions Logo
Inc. Magazine Unveils 30th Annual List of America's Fastest-Growing Private Companies - the Inc. 500
31 août 2011 10h00 HE | Synapse Marketing Solutions
NEW YORK, Aug. 31, 2011 (GLOBE NEWSWIRE) -- NEW YORK, August 23, 2011 - Inc. magazine today ranked Synapse Marketing Solutions (Lancaster, PA) No. 396 on its 30th annual Inc. 500, an exclusive ranking...